A Multi-center, Parallel-group, Double-blind, Placebo-controlled Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability and the Pharmacokinetic Properties of SAR228810 Given as IV Infusion or as SC Injection in Patients With Mild to Moderate Alzheimer's Disease.

Trial Profile

A Multi-center, Parallel-group, Double-blind, Placebo-controlled Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability and the Pharmacokinetic Properties of SAR228810 Given as IV Infusion or as SC Injection in Patients With Mild to Moderate Alzheimer's Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Mar 2015

At a glance

  • Drugs SAR 228810 (Primary) ; SAR 228810 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 24 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
    • 18 Jun 2014 Planned End Date changed from 1 Jan 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
    • 28 Apr 2014 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top